Cargando…

Real world use of loteprednol etabonate ophthalmic gel 0.5% in cases representative of comorbid pathologies responding to minimally invasive glaucoma surgery

PURPOSE: With the increasing use of minimally invasive surgical techniques for intraocular pressure (IOP) lowering in glaucoma patients, there is a need to examine best practices regarding the postoperative management of these patients. Corticosteroids, though effective in controlling postoperative...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sheppard, JD, Singh, IP
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6645598/ https://www.ncbi.nlm.nih.gov/pubmed/31409967 http://dx.doi.org/10.2147/OPTH.S206424

Ejemplares similares

Dose uniformity of loteprednol etabonate ophthalmic gel (0.5%) compared with branded and generic prednisolone acetate ophthalmic suspension (1%)
por: Marlowe, Zora T, et al.
Publicado: (2014)

Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure
por: Sheppard, John D., et al.
Publicado: (2016)

Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop
por: Coffey, Martin J, et al.
Publicado: (2013)

Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use
por: Amon, Michael, et al.
Publicado: (2012)

A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty
por: Khaimi, Mahmoud A
Publicado: (2018)

Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery
por: Comstock, Timothy L, et al.
Publicado: (2011)

Rheological Properties, Dissolution Kinetics, and Ocular Pharmacokinetics of Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%
por: Cavet, Megan E., et al.
Publicado: (2019)

Review of Loteprednol Etabonate 0.5%/Tobramycin 0.3% in the Treatment of Blepharokeratoconjunctivitis
por: Mah, Francis S., et al.
Publicado: (2021)

Dose Uniformity of Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38% Compared with Prednisolone Acetate Ophthalmic Suspension 1%
por: Marlowe, Zora T., et al.
Publicado: (2021)

Ocular Pharmacokinetics of a Novel Loteprednol Etabonate 0.4% Ophthalmic Formulation
por: Schopf, Lisa, et al.
Publicado: (2014)

Loteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trial
por: Fong, Raymond, et al.
Publicado: (2012)

Real-World Use of Loteprednol Etabonate 0.5%/Tobramycin 0.3% Ophthalmic Suspension for the Treatment of Ocular Surface Inflammatory Conditions
por: Deom, James E, et al.
Publicado: (2022)

An update on the surgical management of pterygium and the role of loteprednol etabonate ointment
por: Sheppard, John D, et al.
Publicado: (2014)

Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%: A Review in Post-Operative Inflammation and Pain Following Ocular Surgery
por: Kang, Connie, et al.
Publicado: (2020)

Loteprednol Etabonate for the Treatment of Dry Eye Disease
por: Beckman, Kenneth, et al.
Publicado: (2020)

Practical Guidance for the Use of Loteprednol Etabonate Ophthalmic Suspension 0.25% in the Management of Dry Eye Disease
por: Venkateswaran, Nandini, et al.
Publicado: (2022)

Correction to: Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%: A Review in Post-Operative Infammation and Pain Following Ocular Surgery
por: Kang, Connie, et al.
Publicado: (2020)

Advances in Corticosteroid Therapy for Ocular Inflammation: Loteprednol Etabonate
por: Comstock, Timothy L., et al.
Publicado: (2012)

A retrospective analysis of the postoperative use of loteprednol etabonate gel 0.5% following laser-assisted in situ keratomileusis or photorefractive keratectomy surgery
por: Salinger, Clifford L, et al.
Publicado: (2015)

Cytarabine-Induced Corneal Toxicity: Clinical Features and Relief of Symptoms with Loteprednol Etabonate 0.5% in Two Patients
por: Özcan, Gökçen, et al.
Publicado: (2021)

Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two Phase III clinical studies
por: Fong, Raymond, et al.
Publicado: (2019)

Binary Polymeric Surfactant Mixtures for the Development of Novel Loteprednol Etabonate Nanomicellar Eyedrops
por: Tampucci, Silvia, et al.
Publicado: (2023)

Efficacy of olopatadine hydrochloride 0.1%, emedastine difumarate 0.05%, and loteprednol etabonate 0.5% for Chinese children with seasonal allergic conjunctivitis: a randomized vehicle‐controlled study
por: Liu, Rui‐fen, et al.
Publicado: (2016)

Loteprednol etabonate: Dematiaceous fungal colonisation by Bipolaris species in the left eye: case report
Publicado: (2020)

Comparison between Betamethasone, Fluorometholone and Loteprednol Etabonate on intraocular pressure in patients after keratorefractive surgery
por: Shokoohi-Rad, Saeed, et al.
Publicado: (2017)

Efficacy and safety of a 3-month loteprednol etabonate 0.5% gel taper for routine prophylaxis after photorefractive keratectomy compared to a 3-month prednisolone acetate 1% and fluorometholone 0.1% taper
por: Mifflin, Mark D, et al.
Publicado: (2017)

Effect of Topical Loteprednol on Intraocular Pressure After Selective Laser Trabeculoplasty for Open-Angle Glaucoma
por: Rebenitsch, Ronald L., et al.
Publicado: (2013)

A Prospective Study of Cyclosporine A 0.1% Combined with Loteprednol 0.2% vs Cyclosporine A 0.05% Alone in the Treatment of Dry Eye
por: Hovanesian, John, et al.
Publicado: (2023)

Comparison of Drug Concentrations in Human Aqueous Humor after the Administration of 0.3% Gatifloxacin Ophthalmic Gel, 0.3% Gatifloxacin and 0.5% Levofloxacin Ophthalmic Solutions
por: Ding, Wenting, et al.
Publicado: (2015)

Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial
por: Goldberg, Ivan, et al.
Publicado: (2014)

Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects
por: Napolitano, Antonella, et al.
Publicado: (2013)

Critical appraisal of loteprednol ointment, gel, and suspension in the treatment of postoperative inflammation and pain following ocular and corneal transplant surgery
por: Pirouzian, Amir, et al.
Publicado: (2014)

Use of loteprednol for routine prophylaxis after photorefractive keratectomy
por: Mifflin, Mark D, et al.
Publicado: (2012)

Comparison of Loteprednol with Fluorometholone after Myopic Photorefractive Keratectomy
por: Karimian, Farid, et al.
Publicado: (2017)

Topical Treatment of Truncal Acne with Tretinoin Lotion 0.05% and Azelaic Acid Foam
por: St. Surin-Lord, Sharleen, et al.
Publicado: (2020)

A study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertension
por: Rhee, Douglas J, et al.
Publicado: (2008)

The effect of loteprednol suspension eye drops after corneal transplantation
por: Chen, Yingxin, et al.
Publicado: (2021)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events
por: Tsumura, Toyoaki, et al.
Publicado: (2012)

Comorbidities in patients with COPD and pulmonary rehabilitation: do they matter?
por: Franssen, Frits M.E., et al.
Publicado: (2014)

Safety of Fixed-Combination Bimatoprost 0.03%/Timolol 0.5% Ophthalmic Solution at 6 Months in Chinese Patients with Open-Angle Glaucoma or Ocular Hypertension
por: Sun, Xinghuai, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m8q4mo5lr6uht3hj85bjn5gm6m